Yusuke Shiozawa

Yusuke Shiozawa

Auto-generated profile, based on publicly available information

Yusuke Shiozawa

Laboratory of Molecular Analysis, Nippon Medical School, Tokyo 113-8602, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Cancer Cell
Verified
Journal Article
Closed access
YFYoichi Fujii
Yoichi Fujii
YSYusuke Sato
Yusuke Sato
HSHiromichi Suzuki
Hiromichi Suzuki
NKNobuyuki Kakiuchi
Nobuyuki Kakiuchi
TYTetsuichi Yoshizato
Tetsuichi Yoshizato
SOSeishi Ogawa
Seishi Ogawa

26 July 2023 in Nature
Verified
Journal Article
Open access
PDF file
TNTomomi Nishimura
Tomomi Nishimura
NKNobuyuki Kakiuchi
Nobuyuki Kakiuchi
KYKenichi Yoshida
Kenichi Yoshida
TSTakaki Sakurai
Takaki Sakurai
TKTatsuki R. Kataoka
Tatsuki R. Kataoka
SOSeishi Ogawa
Seishi Ogawa
Recent studies have documented frequent evolution of clones carrying common cancer mutations in apparently normal tissues, which are implicated in cancer development1–3. However, our knowledge is still missing with regard to what additional driver events take place in what order, before one or more of these clones in normal tissues ultimately evolve to cancer. Here, using phylogenetic analyses of multiple microdissected samples from both cancer and non-cancer lesions, we show unique evolutionary histories of breast cancers harbouring der(1;16), a common driver alteration found in roughly 20% of breast cancers. The approximate timing of early evolutionary events was estimated from the mutation rate measured in normal epithelial cells. In der(1;16)(+) cancers, the derivative chromosome was acquired from early puberty to late adolescence, followed by the emergence of a common ancestor by the patient’s early 30s, from which both cancer and non-cancer clones evolved. Replacing the pre-existing mammary epithelium in the following years, these clones occupied a large area within the premenopausal breast tissues by the time of cancer diagnosis. Evolution of multiple independent cancer founders from the non-cancer ancestors was common, contributing to intratumour heterogeneity. The number of driver events did not correlate with histology, suggesting the role of local microenvironments and/or epigenetic driver events. A similar evolutionary pattern was also observed in another case evolving from an AKT1-mutated founder. Taken together, our findings provide new insight into how breast cancer evolves.

30 August 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
TITomoya Isobe
Tomoya Isobe
MTMasatoshi Takagi
Masatoshi Takagi
ASAiko Sato-Otsubo
Aiko Sato-Otsubo
ANAkira Nishimura
Akira Nishimura
GNGenta Nagae
Genta Nagae
JTJunko Takita
Junko Takita
KMT2A-rearranged infant acute lymphoblastic leukemia (ALL) represents the most refractory type of childhood leukemia. To uncover the molecular heterogeneity of this disease, we perform RNA sequencing, methylation array analysis, whole exome and targeted deep sequencing on 84 infants with KMT2A-rearranged leukemia. Our multi-omics clustering followed by single-sample and single-cell inference of hematopoietic differentiation establishes five robust integrative clusters (ICs) with different master transcription factors, fusion partners and corresponding stages of B-lymphopoietic and early hemato-endothelial development: IRX-type differentiated (IC1), IRX-type undifferentiated (IC2), HOXA-type MLLT1 (IC3), HOXA-type MLLT3 (IC4), and HOXA-type AFF1 (IC5). Importantly, our deep mutational analysis reveals that the number of RAS pathway mutations predicts prognosis and that the most refractory subgroup of IC2 possesses 100% frequency and the heaviest burden of RAS pathway mutations. Our findings highlight the previously under-appreciated intra- and inter-patient heterogeneity of KMT2A-rearranged infant ALL and provide a rationale for the future development of genomics-guided risk stratification and individualized therapy.

2 January 2018 in Pediatrics International
Verified
Journal Article
Closed access
PDF file
YSYusuke Shiozawa
Yusuke Shiozawa
RIRyo Inuzuka
Ryo Inuzuka
TSTakahiro Shindo
Takahiro Shindo
RMRyo Mafune
Ryo Mafune
THTaiyu Hayashi
Taiyu Hayashi
AOAkira Oka
Akira Oka

26 March 2026 in Blood
Verified
Journal Article
Open access
KNKoutarou Nishimura
Koutarou Nishimura
TITomoya Isobe
Tomoya Isobe
TSTsukasa Shigehiro
Tsukasa Shigehiro
MNMasaki Nomura
Masaki Nomura
WZWeijia Zang
Weijia Zang
DIDaichi Inoue
Daichi Inoue
NUTM1 rearrangement defines a significant subset of B-cell acute lymphoblastic leukemia (B-ALL), particularly in infants lacking KMT2A rearrangements, yet its underlying molecular characteristics remain poorly understood. Here, we establish that NUTM1-rearranged (NUTM1-r) leukemia is a discrete entity characterized by a unique transcriptional and epigenetic landscape, notably featuring global DNA hypomethylation, irrespective of the 5′ fusion partner. Functional interrogation of NUTM1 fusions reveals a dual oncogenic role: they drive commitment toward the B-lymphoid lineage while concurrently conferring potent leukemic stem cell properties. Strikingly, expression of a representative fusion, BRD9-NUTM1, is sufficient to induce serially transplantable B-cell progenitor, prepro–B-like leukemia in vivo, faithfully recapitulating the key molecular and immunophenotypic features of human NUTM1-r B-ALL. Mechanistically, NUTM1 fusions establish an aberrant chromatin state, marked by global enhancement of H3K27 acetylation and the creation of distinctive open chromatin regions that co-opt both B-lineage and stemness-related transcriptional programs, including those involving NF-κB and posterior HoxA genes. In stark contrast to resistant KMT2A-rearranged leukemias, NUTM1-r leukemic cells exhibit a profound sensitivity to chemotherapy. This vulnerability is mechanistically linked to the leukemia's dependence on active transcription. Our findings delineate the unique molecular profile of NUTM1-r leukemias, revealing specific vulnerabilities that rationalize their favorable clinical outcomes and suggest opportunities for modified therapeutic strategies.

21 August 2026 in Science Advances
Verified
Journal Article
Closed access
HKHiroshi Kobayashi
Hiroshi Kobayashi
SWShintaro Watanuki
Shintaro Watanuki
YSYusuke Shiozawa
Yusuke Shiozawa
MOMotohiko Oshima
Motohiko Oshima
SKShuhei Koide
Shuhei Koide
KTKeiyo Takubo
Keiyo Takubo
Hematopoietic stem cells (HSCs) constitute an organized hematopoietic system that undergoes age-related alterations, including increased platelet production and decreased erythropoiesis. The fundamental mechanisms driving these shifts remain incompletely understood. We used single-cell RNA sequencing data to show that old HSCs contain two distinct transcriptional programs: one shared with megakaryocytes and the other reflecting the most primitive HSC state. Developmental time-series profiling further suggests that the acquisition of these programs begins early in life, with the primitive module rising prenatally and megakaryocytic priming emerging after birth. Using a fine-tuned Geneformer (transformer-based deep learning model) to capture higher-order differences between young and old HSCs, coupled with transcriptomic and epigenetic profiling, as well as transcription factor screens, we identified Pbx1 as a key regulator of these age-related transcriptional and differentiation changes. Specifically, Pbx1 suppresses erythroid differentiation by repressing Gata1 expression. These findings provide insight into HSC aging and may inform approaches to modulate age-associated HSC dysfunction.